Septic Shock Clinical Trial
Official title:
Effects of Endotoxin Absorption and Cytokine Removal Hemofilter on Patients With Severe Septic Shock
Verified date | March 2021 |
Source | National Taiwan University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In recent years, many studies have pointed out that bacterial toxin and cytokine storm are the main causes of shock and multiple organ failure in patients with sepsis. Endotoxin is the main vehicle for systemic inflammatory reaction caused by gram-negative bacteria which induce sepsis. Endotoxin binds to Toll- Like receptor 4 (TLR4) trigger a cytokine storm. The amount of endotoxin is associated with shock, insufficient intestinal perfusion, and poor prognosis. Therefore, clinicians try to use various methods to antagonize the action of endotoxin, which can reduce the cytokine storm and inflammatory response to improve the prognosis of sepsis. Continuous venous venous hemofiltration plays a role in blood purification in septic shock. With different hemofiltration filters, it has different effects. By removing the inflammatory mediators caused by bacterial toxins and cytokines, shock can be improved. The study plans to receive patients with septic shock and use a hemofiltration filter that adsorbs endotoxin and removes cytokines (oXiris, Baxter Healthcare) to perform continuous venous venous hemofiltration in addition to basic septic shock resuscitation. The effect on the concentration of cytokines in the blood, the infusion dose of inotropics, the fluid balances, and the degree of organ damage was evaluated. It is hoped that the results of this pilot study can lead us to subsequent randomized clinical trials to explore whether this filter can improve the prognosis of septic shock patients.
Status | Completed |
Enrollment | 12 |
Est. completion date | August 20, 2020 |
Est. primary completion date | July 17, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - Patients who meet all criteria (A+B+C): - A) Identified infection source under adequate treatment - B) Sepsis (the sequential organ failure assessment score rise 2 points or more) - C) Severe septic shock (serum lactate > 2 mmol/L; need continuous norepinephrine infusion to maintain adequate blood pressure, of which dosage is > 0.2 mcg/kg/min for more than 1 hour or >0.1 mcg/kg/min for more than 3 hours ) Exclusion Criteria: - Onset of severe septic shock more than 24 hours - Received continuous renal replacement therapy within 24 hours before enrollment - Serum white blood cell count count < 1000 cells/µL or Platelet count < 50000 cells/µL - History of allergy to heparin - Received cardiopulmonary resuscitation within 4 weeks before enrollment - ICU admission due to severe septic shock within 2 months - Patients or Family had chosen palliative care and signed an agreement to deny aggressive treatment - Pregnancy - APACHE II Score > 30 at enrollment - Non-native speakers |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference of serum interleukin-6 level | Comparison to enrollment or between 2 groups | 24 hours | |
Secondary | Difference of serum interleukin-6 level | Comparison to enrollment or between 2 groups | 48 hours | |
Secondary | Difference of serum interleukin-6 level | Comparison to enrollment or between 2 groups | 72 hours | |
Secondary | Difference of serum interleukin-1ß level | Comparison to enrollment or between 2 groups | 24 hours | |
Secondary | Difference of serum interleukin-1ß level | Comparison to enrollment or between 2 groups | 48 hours | |
Secondary | Difference of serum interleukin-1ß level | Comparison to enrollment or between 2 groups | 72 hours | |
Secondary | Difference of serum interleukin-10 level | Comparison to enrollment or between 2 groups | 24 hours | |
Secondary | Difference of serum interleukin-10 level | Comparison to enrollment or between 2 groups | 48 hours | |
Secondary | Difference of serum interleukin-10 level | Comparison to enrollment or between 2 groups | 72 hours | |
Secondary | Difference of serum procalcitonin level | Comparison to enrollment or between 2 groups | 24 hours | |
Secondary | Difference of serum procalcitonin level | Comparison to enrollment or between 2 groups | 48 hours | |
Secondary | Difference of serum procalcitonin level | Comparison to enrollment or between 2 groups | 72 hours | |
Secondary | Difference of mean arterial pressure | Comparison to enrollment | 24 hours | |
Secondary | Difference of mean arterial pressure | Comparison to enrollment | 48 hours | |
Secondary | Difference of mean arterial pressure | Comparison to enrollment | 72 hours | |
Secondary | Difference of cardiac output | Comparison to enrollment | 24 hours | |
Secondary | Difference of cardiac output | Comparison to enrollment | 48 hours | |
Secondary | Difference of cardiac output | Comparison to enrollment | 72 hours | |
Secondary | Difference of norepinephrine infusion rate | Comparison to enrollment | 24 hours | |
Secondary | Difference of norepinephrine infusion rate | Comparison to enrollment | 48 hours | |
Secondary | Difference of norepinephrine infusion rate | Comparison to enrollment | 72 hours | |
Secondary | Difference of the sequential organ failure assessment score | Comparison to enrollment or between 2 groups | 24 hours | |
Secondary | Difference of the sequential organ failure assessment score | Comparison to enrollment or between 2 groups | 48 hours | |
Secondary | Difference of the sequential organ failure assessment score | Comparison to enrollment or between 2 groups | 72 hours | |
Secondary | Difference of serum endocan level | Comparison to enrollment or between 2 groups | 24 hours | |
Secondary | Difference of serum endocan level | Comparison to enrollment or between 2 groups | 48 hours | |
Secondary | Difference of serum endocan level | Comparison to enrollment or between 2 groups | 72 hours | |
Secondary | Difference of serum diamine oxidase level | Comparison to enrollment or between 2 groups | 24 hours | |
Secondary | Difference of serum diamine oxidase level | Comparison to enrollment or between 2 groups | 48 hours | |
Secondary | Difference of serum diamine oxidase level | Comparison to enrollment or between 2 groups | 72 hours | |
Secondary | Difference of daily IV fluids | Comparison between 2 groups | 24 hours | |
Secondary | Difference of daily IV fluids | Comparison between 2 groups | 48 hours | |
Secondary | Difference of daily IV fluids | Comparison between 2 groups | 72 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03649633 -
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
|
Phase 1/Phase 2 | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Completed |
NCT05629780 -
Temporal Changes of Lactate in CLASSIC Patients
|
N/A | |
Recruiting |
NCT04796636 -
High-dose Intravenous Vitamin C in Patients With Septic Shock
|
Phase 1 | |
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT05066256 -
LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Recruiting |
NCT02565251 -
Volemic Resuscitation in Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT02580240 -
Administration of Hydrocortisone for the Treatment of Septic Shock
|
N/A | |
Recruiting |
NCT02676427 -
Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
|
||
Not yet recruiting |
NCT02547467 -
TOADS Study: TO Assess Death From Septic Shock.
|
N/A | |
Terminated |
NCT02335723 -
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
|
N/A | |
Completed |
NCT02638545 -
Hemodynamic Effects of Dexmedetomidine in Septic Shock
|
Phase 3 | |
Completed |
NCT02079402 -
Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care
|
Phase 4 | |
Completed |
NCT02306928 -
PK Analysis of Piperacillin in Septic Shock Patients
|
N/A |